Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contrast-enhanced MRI Examination of Cerebral Neoplastic Enhancing Lesions: Comparison of Diagnostic Efficacy of Gd-DOTA 0.5M and Gadobutrol 1.0 M at 0.1 mmol/kg Body Weight: Intraindividual Comparison Clinical Study.

NCT00764387 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00764387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00764387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contrast-enhanced MRI Examination of Cerebral Neoplastic Enhancing Lesions: Comparison of Diagnostic Efficacy of Gd-DOTA 0.5M and Gadobutrol 1.0 M at 0.1 mmol/kg Body Weight: Intraindividual Comparison Clinical Study.
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2008
Completion date
May 31, 2009
Enrollment
166 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neoplastic cns lesions